24/7 Wall Street
17 Nov 2026, 16:52 UTC · 19m ago
Amgen Has Raised Its 2026 Outlook Twice, and $1,000 From Five Years Ago Is Now Worth More Than $2,500
Impact · against what's priced in
Amgen's latest guidance raise is a marginal catalyst as the market had already priced in the August updates; however, the commitment to stable 2027 margins provides new support for the valuation. The stock remains a bet on MariTide's success, which the market is not yet pricing in.
- AMGN+0.20
Challenges what's priced in
- The price assumes
The raised full-year revenue guidance of $38.2-$39.4 billion and non-GAAP EPS of $22.30-$23.50 are fully reflected.





